When telephone lines go down, or Internet connections are lost, our communities temporarily come to a halt. What if something similar were found to be happening in Parkinson's? This is the focus of Dr. Schmitz and her team at the PDF Research Center at Columbia University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Profile characterization of Parkinson's disease in Mexico: ReMePARK study].
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
Gac Med Mex 2013 Sep-Oct; 149(5):497-501
Authors: Amin Cervantes-Arriaga, Mayela Rodríguez-Violante, Minerva López-Ruiz, Ingrid Estrada-Bellmann, Carlos Zuñiga-Ramírez, Elisa Otero-Cerdeira, Azyadeh Camacho-Ordoñez, Paulina González-Latapi, Hugo Morales-Briceño, Daniel Martínez-Ramírez
Instituto Nacional de Neurología y Neurocirugía, México, D.F. firstname.lastname@example.org.
Introduction: The Mexican Registry of Parkinson´s disease (ReMePARK) is nested within a multicentric cohort aimed to describe motor, non-motor, and genetic determinants of Parkinson's disease in Mexican patients. Material and methods: To date, clinical and demographic data from 1,083 subjects has been obtained. Here we present the demographic and clinical data of the current sample along with its comparison with international reports. Results: A total of 607 male and 476 female subjects with Parkinson's disease were included. The mean age of the patients was 64.7 ± 12.9 years. The time from onset of symptoms to diagnosis was 2.4 ± 2.6 years. About 34% of subjects had only elementary education. Of the subjects, 54.4% were under treatment with dopamine agonists. Conclusion: Subjects with Parkinson's disease incorporated into ReMePARK are comparable with other international registries, with the exception of the years of formal education, time to diagnosis, and the use of dopamine agonists. The characterization of the Mexican population with Parkinson's disease will improve diagnosis and therapeutic management as well as define research efforts in this area. Finally, registry future directions are presented.
PMID: 24108335 [PubMed - as supplied by publisher]